4D Molecular Therapeutics (FDMT) Invested Capital (2019 - 2026)

4D Molecular Therapeutics (FDMT) has 8 years of Invested Capital data on file, last reported at $451.8 million in Q1 2026.

• Invested Capital for Q1 2026 came in at $451.8 million, down 3.81% year-over-year; the trailing twelve-month figure through Mar 2026 was $451.8 million (down 3.81% YoY), and the FY2025 annual result was $505.7 million, down 0.97% from the prior year.
• Invested Capital retreated to $451.8 million in Q1 2026 per FDMT's latest filing, from $505.7 million in the prior quarter.
• Over five years, Invested Capital peaked at $600.6 million in Q1 2024 and troughed at $218.6 million in Q1 2023.
• A 5-year average of $394.3 million and a median of $369.0 million in 2025 frame the typical range for Invested Capital.
• The sharpest annual moves came in 2024 and 2025: Invested Capital soared 174.72% in 2024, then slumped 33.27% in 2025.
• A 5-year view of Invested Capital shows it stood at $231.3 million in 2022, then surged by 33.07% to $307.8 million in 2023, then soared by 65.87% to $510.6 million in 2024, then dropped by 0.97% to $505.7 million in 2025, then retreated by 10.65% to $451.8 million in 2026.
• Business Quant data shows FDMT's Invested Capital at $451.8 million in Q1 2026, $505.7 million in Q4 2025, and $369.0 million in Q3 2025.